Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof

A technology of cells and donors, applied in the field of cell compositions derived from dead donors for promoting graft tolerance and its manufacture and use, which can solve the problems of donors having no medical benefit, infection, etc.

Pending Publication Date: 2021-07-23
MEDEOR THERAPEUTICS INC
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, apheresis can take up to six hours, may need to be repeated over several days to obtain a sufficient number of HSPCs, and carries risks of infection and clotting
In addition, there is no medical benefit to the donor from donating HSPCs, regardless of the method, so many individuals are reluctant to donate HSPCs unless they have a direct family or personal relationship to the recipient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
  • Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
  • Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0196] The following describes a method of preparing a cell composition containing CD34 derived from the bone marrow of a deceased donor according to one embodiment of the invention + CD3 of cells and blood derived from dead donors + cell.

[0197] figure 1 is a flowchart illustrating a method of preparing a cell composition comprising CD34 derived from the bone marrow of a deceased donor according to one embodiment of the present invention + CD3 of cells and blood derived from dead donors + cell. The method comprises a series of steps described in more detail below. The method comprises the following steps: collecting tissue; preparing bone marrow; preparing blood; preparing buffer; enriching CD34 from bone marrow + cells; dividing combined substances into individual doses; and cryopreservation. The order of steps described here is for illustration purposes only. These methods are not limited to a particular order of steps, although those skilled in the art will appreci...

example 2

[0206] For the preparation of CD34-containing + cells and CD3 + Exemplary methods of cell product MDR-104 are described below. This method provides two doses, each of these doses contains 100x10 per kg of recipient weight from a single deceased donor 6 T cells and >4x10 per kg recipient weight 6 CD34 + cell. Each dose supports the transplantation of one kidney from a deceased donor to a different recipient. This product also contains every 10 5 Each cell >500 colony forming units (CFU). This product can be further characterized to determine IL-2 release as well as active CD34 + cells and CD3 + percentage of cells.

[0207] Figure 13 is a flowchart illustrating a method of preparing a cell composition according to an embodiment of the present invention. As described in more detail below, CD3 + Cells were prepared from whole blood in MDR-T treatment, CD34 + Prepared from bone marrow in MDR-E treatment and combined with prepared CD3 in MDR-34T treatment + cells and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides cellular compositions that contain CD34+ cells derived from bone marrow of a decease donor and CD3+ cells derived from non-bone marrow of the deceased donor. The compositions are useful to promote mixed chimerism in recipients of solid organ transplants. The invention also provides methods of making and using such compositions. In certain embodiments, the invention further provides methods of analyzing and preparing blood and blood components from a deceased donor for use in compositions of the invention to promote mixed chimerism in solid organ transplant recipients.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 62 / 732,823, filed September 18, 2018; U.S. Provisional Application No. 62 / 732,827, filed September 18, 2018; U.S. Provisional Application No. 62 / 732,827, filed September 18, 2018 Application No. 62 / 732,830; the benefit and priority of U.S. Provisional Application No. 62 / 732,832, filed September 18, 2018, the contents of each of these U.S. Provisional Applications are incorporated herein by reference. technical field [0003] The present invention relates generally to therapeutic compositions comprising cells derived from dead donors and methods of making and using the same. Background technique [0004] Nearly 35,000 organ transplants are performed in the United States each year. The main complication of organ transplantation is rejection of the organ by the recipient's immune system. To avoid organ rejection, most transplant recipients must take immunosuppres...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/14A61K35/17A61K35/26A61K35/407A61K35/545A61K35/28A61P37/06C12N5/071C12N5/0789
CPCA61P37/06A61K35/28A61K35/14A61K35/26A61K35/407C12N5/0669A61K35/17A61K35/545A61K2300/00
Inventor M·兹达诺夫斯基C·苏伊尔D·S·巴蒂
Owner MEDEOR THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com